medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2013, Number 4

<< Back Next >>

Salud Mental 2013; 36 (4)

Parkinson’s disease: neurological bases for psychiatrists

Chávez-León E, Ontiveros-Uribe MP, Carrillo-Ruiz JD

Language: Spanish
References: 38
Page: 315-324
PDF size: 413.75 Kb.


ABSTRACT

Parkinson’s disease is a progressive and degenerative disease due to the loss of the substantia nigra dopaminergic neurons in the mesencephalon. Its manifestations are: tremor at rest, rigidity and slowing of movements, and alterations in posture and gait. The early onset of dementia or the presence of hallucinations, not related to the dopaminergic treatment, are associated with the presence of dementia with Lewy bodies (DLB) or Alzheimer’s disease. The scales used to assess the stage and severity of Parkinson’s disease are: the scale of Stages of Hoehn and Yahr, and the Unified Parkinson’s Disease Rating Scale. Although there is not a drug that stops the progression of Parkinson’s disease, the current treatment for this illness consist in: a) dopamine replacement through the use of its precursor, levodopa, b) administering substances, like ropinirole, pramipexole, and bromocriptine, that increase dopamine activity to stimulate their receptors, and c) inhibiting the enzymes that destroy dopamine as the catechol- O-methyltransferase with entacapone, and monoamine oxidase type B (MAOB) with selegiline and rasagiline. Surgical treatment of Parkinson’s disease consists of ablative procedures and deep brain stimulation. This review describes their indications, administration and side effects.


REFERENCES

  1. Carson AJ, Zeman A, Stone J, Sharpe MC. Neurology and neurosurgery. En: Levenson JL (ed.). Textbook of psychosomatic medicine. Psychiatric care of the medically ill. Washington: APPI; 2011.

  2. Lerner AJ, Riley D. Neuropsychiatric aspects of dementias associated with motor dysfunction. En: Yudofsky SC, Hales RE (eds). The American psychiatric publishing textbook of neuropsychiatry and behavioral sciences. Quinta edición. Arlington: APPI; 2008.

  3. Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 2002;14:223-236.

  4. Goetz CG. Charcot on Parkinson’s disease. Mov Disord 1986;1(1):27-32.

  5. Kempster PA, Hurwitz B, Lees AJ. A new look at James Parkinson’s Essay on the Shaking Palsy. Neurology 2007;69(5):482-485.

  6. Louis ED. The shaking palsy, the first forty-five years: a journey through the British literature. Mov Disord 1997;12(6):1068-1072.

  7. Lees AJ. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson’s 250th birthday. Mov Disord 2007;22(Supl 17):s327-s334.

  8. Parent M, Parent A. Substantia nigra and Parkinson’s disease: a brief history of their long and intimate relationship. Can J Neurol Sci 2010;37(3):313-319.

  9. Marsh L, Margolis RL. Neuropsychiatric aspects of movement disorders. En: Kaplan, Sadock’s (eds.). Comprehensive textbook of psychiatry. Philadelphia: Lippincott Willimas & Wilkins; 2009; pp.481-493.

  10. Malaspina D, Corcoran C, Schobel S, Hamilton SP. Epidemiological and genetic aspects of neuropsychiatric disorders. En: Yudofsky SC, Hales RE (eds). The American psychiatric publishing textbook of neuropsychiatry and behavioral sciences. Quinta edición. Arlington: APPI; 2008.

  11. Sun Y, Chang YH, Chen HF, Su YH et al. Risk of Parkinson disease onset in patients with diabetes. A 9- year population- based cohort study with age and sex stratifications. Diabetes 2012;35:1047-1049.

  12. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits : Parallel substrates for motor, oculomotor, prefrontal and limbic functions. Prog Brain Res 1990;85:119-146.

  13. Hoehn MM, Yahr MD. Pakinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.

  14. Fahn S, Elton R. Miembros del Comité de Desarrollo de la UPDRS En: Fahn S, Marsden CD, Calne DB, http://www.mdvu.org/library/ratingscales/pd/updrs.pdf. Accesada el 12 de abril de 2012.

  15. Goetz CG, Tilley BC, Shaftman ST et al. Movement disorder societysponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS- UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008:23(15):2129-2170.

  16. Rodríguez-Oroz MC, Jahanshahi M, Krack P et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 2009;8:1128-1139.

  17. Uchivama T, Sakakibara R, Yamamoto T et al. Urinary dysfunction in early and untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011;82:1382-1386.

  18. Ahlskog JE. Cheaper, simpler, and better: Tips for treating seniors with Parkinson disease. Mayo Clin Proc 2011;86(12):1211-1216.

  19. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54(1):93-101.

  20. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287(13):1653-1661.

  21. Olanow CW, Hauser RA, Jankovic J et al. A randomized, doubleblind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008;23(15):2194-2201.

  22. Ahlskog JE. Parkinson’s disease: does vigorous exercise have a neuroprotective effect in Parkinson’s disease? Neurology 2011;77:288-294.

  23. Estañol-Vidal B, Sentíes Madrid H. Enfermedad de Parkinson. En: De la Fuente JR, Heinze G (eds). Salud mental y medicina psicológica. México: McGraw Hill, 2012.

  24. Miyasaki JM, Martin W, Suchowersky O et al. Practice parameter: Initiation of treatment for Parkinson’s disease: an evidence- based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.

  25. Hitzema N, Rafii F. Am Fam Physician 2009; 80 (1): 28- 30.

  26. Leentjens AFG. The role of dopamine agonists in the treatment of depression in patients with Parkinson’s disease. A systematic review. Drugs 2011;71(3):273-286.

  27. Hauser RA, Rascol O, Korczyn AD et al. Ten- year follow- up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22(16):2409-2417.

  28. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(21) (Supl 4):S1-S136.

  29. Jain L, Benko R, Safranek S. Which drugs work best for early Parkinson’s disease? J Fam Pract 2012;61(2):106-108.

  30. Chávez-León E, Del Bosque Garza J, Ontiveros-Uribe MP. Manual de psicofarmacología. México: Asociación Psiquiátrica Mexicana; 2007.

  31. Schapira A. Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: A review of symptomatic and potential diseasemodifying effects. CNS Drugs 2011;25(12):1061-1071.

  32. Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.

  33. Sandoval LI, Jiménez F, Soto J et al. Resultados del tratamiento quirúrgico de la enfermedad de Parkinson en la Unidad de Neurocirugía Funcional, Estereotaxia y Radiocirugía, del Hospital General de México en el período de 1992 a 2009. Rev Mex Neuroci 2010;11(1):20-25.

  34. Behari M, Singhal KK. Cell based therapies in Parkinson’s disease. Ann Neurosc. 2011; 18 (2): 76- 83.

  35. Weaver FM, Follet K, Stern M et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301(1):63-73.

  36. McNeely ME, Hershey T, Campbell MC et al. Effects of deep brain stimulation of dorsal versus ventral subthalamic nucleus regions on gait and balance in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011;82:1250-1255.

  37. Castrioto A, Lozano AM, Poon YY et al. Ten-year outcome of subthalamic stimulation in Parkinson disease: A blinded evaluation. Arch Neurol 2011;68:1550-1556.

  38. Carrillo-Ruiz J, Velasco F, Jiménez F et al. Prelemniscal radiation neuromodulation in Parkinson´s disease treatment. En: Topics in Neuromodulation treatment. José D. Carrillo-Ruiz (ed). Croacia: Intech; 2012; pp. 63-86.




2020     |     www.medigraphic.com